low - Rare disease treatments are medically necessary, non-discretionary healthcare spending with minimal correlation to GDP growth. ATTR-CM is a progressive, fatal disease where patients and physicians prioritize efficacy over economic conditions. Insurance coverage (Medicare, commercial) insulates demand from consumer spending cycles. However, severe recessions could pressure hospital budgets and diagnostic testing rates, potentially slowing new patient identification.

Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress NPV of future cash flows for pre-profitable biotech, disproportionately impacting valuation multiples - BridgeBio trades at 40x P/S, making it sensitive to risk-free rate changes that affect growth stock valuations; (2) Increased financing costs if company needs to raise additional capital through convertible debt, though current $1.1B cash position provides near-term buffer. Conversely, falling rates would benefit valuation multiples and reduce cost of capital for future financings.

growth - BridgeBio attracts growth-oriented biotech investors focused on commercial execution of newly launched rare disease therapies with multi-billion peak sales potential. The 110% one-year return and 40x P/S valuation reflect momentum-driven trading as Attruby launch progresses. Institutional healthcare specialists (Perceptive Advisors, RA Capital, Farallon) dominate ownership given clinical/commercial expertise required. Not suitable for value or income investors given negative earnings, no dividend, and high valuation multiples. Risk-tolerant growth investors accept binary clinical/commercial risk for asymmetric upside if Attruby captures significant ATTR-CM market share.